English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Parkinsonu0027s disease (PD) is the second most common neurodegenerative disease whereby the number of diagnosed patients rises by 3–4% each year creating an ever-expanding social, medical and financial burden. Symptoms such as rigidity, postural instability and bradykinesia are due to diminished levels of dopamine within the brain. More specifically dopamine cell bodies are located in the substantia nigra (SN) and dopamine is released in the striatum. Motor dysfunction becomes evident with a 70–80% loss of dopamine in the striatum. The cause of PD is currently unknown and hence most treatments are aimed at minimizing symptoms not preventing the cause. However, it is known that metabolic status, more specifically calorie restriction is neuroprotective in PD (Bayliss and Andrews, 2013).

Ghrelin is the metabolic link connecting calorie restriction to neuroprotection